Yuhan Corp. Receives $45 Million Milestone Payment for 'Leclaza' Following Commercial Launch in China
Yuhan Corp. will receive a $45 million milestone payment from Janssen Biotech after the commercial launch of Leclaza in China, marking a key step in its global expansion strategy.
Yuhan Corp. reported a 190% surge in Q2 operating profit to 45.6 billion won, driven by milestone payments and royalties from its cancer drug Lazertinib, with results meeting market expectations.
#YonhapInfomax #YuhanCorp #OperatingProfit #Lazertinib #MilestonePayment #Q2Earnings #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=74532
Yuhan Corp. Posts Q2 Operating Profit of 45.6 Billion Won, Up 190%—'Milestone Payment from Lazertinib Reflected' (Comprehensive)
Yuhan Corp. reported a 190% surge in Q2 operating profit to 45.6 billion won, driven by milestone payments and royalties from its cancer drug Lazertinib, with results meeting market expectations.
Yuhan Corp. will receive a $15 million (20.7 billion won) milestone payment from Janssen Biotech after its lung cancer drug Leclaza was officially launched in Japan, marking a key step in the drug's global commercialization.
#YonhapInfomax #YuhanCorp #Leclaza #JanssenBiotech #MilestonePayment #JapanLaunch #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=65606Yuhan to Receive 20.7 Billion Won in Royalties as Leclaza Launches Commercially in Japan
Yuhan Corp. will receive a $15 million (20.7 billion won) milestone payment from Janssen Biotech after its lung cancer drug Leclaza was officially launched in Japan, marking a key step in the drug's global commercialization.
Yonhap Infomax News